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Abstract
Mood stabilising drugs such as lithium (LiCl) and valproic acid (VPA) are the first line agents for treating conditions such as
Bipolar disorder and Epilepsy. However, these drugs have potential developmental effects that are not fully understood.
This study explores the use of a simple human neurosphere-based in vitro model to characterise the pharmacological and
toxicological effects of LiCl and VPA using gene expression changes linked to phenotypic alterations in cells. Treatment with
VPA and LiCl resulted in the differential expression of 331 and 164 genes respectively. In the subset of VPA targeted genes,
114 were downregulated whilst 217 genes were upregulated. In the subset of LiCl targeted genes, 73 were downregulated
and 91 were upregulated. Gene ontology (GO) term enrichment analysis was used to highlight the most relevant GO terms
associated with a given gene list following toxin exposure. In addition, in order to phenotypically anchor the gene
expression data, changes in the heterogeneity of cell subtype populations and cell cycle phase were monitored using flow
cytometry. Whilst LiCl exposure did not significantly alter the proportion of cells expressing markers for stem cells/
undifferentiated cells (Oct4, SSEA4), neurons (Neurofilament M), astrocytes (GFAP) or cell cycle phase, the drug caused a 1.4-
fold increase in total cell number. In contrast, exposure to VPA resulted in significant upregulation of Oct4, SSEA,
Neurofilament M and GFAP with significant decreases in both G2/M phase cells and cell number. This neurosphere model
might provide the basis of a human-based cellular approach for the regulatory exploration of developmental impact of
potential toxic chemicals.
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Introduction
Valproic acid (VPA) and Lithium (LiCl) are commonly used
drugs for the treatment of Bipolar disorder whilst VPA is also used
in the treatment of various types of seizure. Although these agents
have been used for decades, their pharmacological and toxicolog-
ical mechanisms remain poorly understood. Of particular interest
is their contribution to Developmental Neurotoxicity (DNT) as
well as their potential impact on stem cells.
A number of in vitro model systems have been used to study
DNT such as primary rodent cultures [1] as well as stem cell based
models such as the mouse embryonic stem cell test [2,3] and even
mouse embryocarcinoma cells [4]. Human embryonic stem cells
(hESc) can also be used to analyze the in vitro development from
undifferentiated pluripotent cells leading to terminally differenti-
ated cell types, recapitulating the process of early embryonic
development [5]. Indeed, both the hESc and human neuropro-
genitor cell (hNPC) models provide valid and useful tools for
studying DNT. In addition, human models offer the advantage of
better predictive power to man, since extrapolation of results
across species is not an issue [6].
We have previously utilised an NT2.D1 neurosphere based
model of neuronal differentiation to study the effects of a variety of
compounds on neural development [7]. In this study we treated
differentiating NT2.D1 neurospheres with LiCl or VPA in order to
determine their effects using a toxicogenomic and phenotypic
anchoring approach.
Toxicogenomics is a relevant approach for the identification of
biomarkers associated with toxicity and can be employed in
endpoint analysis following exposure to DNTs. To provide
a sensitive and relevant endpoint, aberrations in gene regulation
following exposure to potential teratogens should be linked to toxic
outcomes, such as protein expression, cell proliferation and
morphological changes. This is important, because changes in
gene or protein expression alone may not be sufficient to
differentiate toxicity from biological adaptation following exposure
to a compound [8]. It may also be preferable to measure the
significance of DNT effects on a group of genes from a pathway or
functional category such as those defined in Gene Ontology (GO)
terms because this facilitates the interpretation of the combined
effects of gene changes and may markedly increase significance
[9]. This grouping of genes also acknowledges that genes typically
do not change in isolation and that it would be expected that any
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change that is causally related to toxicity would occur in a set of
related genes rather than a single gene [10].
The objective of this study was to investigate the differential
toxicity observed between LiCl and VPA [7] to further understand
the developmental effects of these compounds. In this study we
used full genome expression analysis combined with gene ontology
(GO) analysis to identify key pathways. We then linked changes in
gene expression to perturbations in differentiated cell populations
and cell proliferation as phenotypic markers to functionally anchor
the gene sets which were modified by toxicant exposure.
Materials and Methods
Materials
All chemicals were of molecular biology grade and were
obtained from Sigma-Aldrich (Poole, UK) unless otherwise stated.
NT2/D1 Cell Culture and Induction of Differentiation
NT2.D1 neurospheres were prepared as described [7]. Briefly
human NT2.D1 cells were cultured in DMEM Glutamax high
glucose medium, with pyruvate (Gibco Invitrogen, Paisley, UK)
containing 10% v/v Heat inactivated foetal bovine serum (Gibco
Invitrogen), 100 units/ml penicillin and 100 mg/ml streptomycin.
Resuspended NT2/D1 cells (26106) were plated into sterile
90 mm diameter non-adherent bacteriological petri dishes (Star-
stedt, Leicester, UK) to generate neurospheres. These cultures
were grown for 2 days before the addition of all-trans-retinoic acid
(RA) to a final concentration of 10 mM together with either LiCl
or VPA. RA only treated neurospheres were used as a control.
Cells were replated and re-fed with RA containing media for the
controls, or media containing RA and toxicants for the treated
cells every 2–3 days. Suspension cultures were maintained for 2
weeks after which time neurospheres were used for analysis.
LiCl and VPA were diluted in sterile PBS to prepare a 100 mM
stock solution and frozen at 220uC. Frozen aliquots were used
only for each change of medium. Cells were treated with either
1 mM LiCl or 0.5 mM VPA. These concentrations have been
previously shown to be within the range of patient plasma levels
[11,12]. In terms of fetal exposure to these drugs, the total
concentration of VPA has been shown to be higher in cord serum
than in the serum of epileptic mothers prescribed this drug
[13,14]. In comparison, lithium appears to equilibriate across the
placenta over a range of maternal concentrations [15].
RNA Extraction
Total RNA was extracted using Trizol reagent (Invitrogen) from
3 separate petri dishes and pooled for each replicate. RNA was
treated with DNAase (Qiagen) for 30 minutes at room temper-
ature. RNA was subsequently purified using the RNAeasy Kit
(Qiagen). RNA quantification was performed using the Nanodrop
1000 (Thermofisher) and sample integrity was determined using
an Agilent Bioanaylser.
Two-Colour Microarray-based Gene Expression Analysis
Full genome analysis was carried out at Birmingham University
Functional genomics laboratory (http://www.genomics.bham.ac.
uk). Briefly, total RNA was extracted as outlined above. RNA
samples were labelled using Agilent’s Quick AMP Labelling kit
and hybridized to Agilent’s Whole human 44 K genome
microarray. Slides were scanned using the Axon GenePix 4000B.
Flow Cytometry
Flow cytometry was performed on disaggregated neurospheres
following 14 days of differentiation. Neurospheres were washed
three times with 10 ml PBS-0.1 M EDTA for 5 min. Washed
neurospheres were pooled from 3 separate Petri dishes, centrifuged
(2176G for 5 min) and resuspended in 5 ml Accutase (PAA
laboratories, UK). Dissociated cells were washed twice with PBS,
fixed in 4% formaldehyde (v/v in PBS) for 20 min on ice, washed
twice in PBS-BS (PBS 0.2% BSA and 0.15% saponin) and
incubated in PBS-BS containing 5% rabbit serum (RS) (Sigma
Aldrich, UK) for 30 min on ice. The cells were then distributed
between four microcentrifuge tubes and incubated with either
mouse anti-NF-M (Millipore, UK) or anti-GFAP antibody
(Millipore, UK), mouse anti-Oct4 antibody (Millipore, UK) and
mouse anti-SSEA4 antibody (Abcam, UK) all diluted 1:500 in
PBS-BS with 5% RS for 1 h on ice. Cells were then washed three
times with PBS-BS, and resuspended in rabbit anti-mouse
Fluoroscein (FITC)-conjugated antibody (Jackson ImmunoRe-
search; diluted 1:250 in PBS-BS with 5% RS) for 30 min on ice.
The cells were washed three times and resuspended in PBS-BS.
The percentage of fluorescent cells was then analysed using
a Quanta SC flow cytometer (Beckman Coulter) gating on single
cells only, with a total cell count of 10000 events. The background
level was estimated by using samples in which the primary
antibody was omitted.
Cell Cycle Analysis
Neurospheres were harvested via centrifugation and washed 3
times in PBS 0.1 M EDTA then dissociated using Accutase (PAA)
for 30 minutes at 37uC. Dissociated cells were washed 3 times in
PBS 0.2% BSA, counted and resuspended in 1 ml PBS. Cells were
fixed by the addition of 9 ml ice cold 70% ethanol and incubation
at 220uC overnight. Subsequently fixed cells were centrifuged at
7176G and washed 3 times with PBS 0.1% BSA. Cells were then
resuspended in 1 ml PBS containing 50 mg propidium iodide and
100 mg heat treated RNAse A and incubated for 3 hours in the
dark at room temperature. Cells were analysed using a Quanta SC
flow cytometer (Beckman Coulter) gating on single cells only with
a total count of 10000 events.
Protein Assay
Protein samples were prepared from NT2/D1 cells and their
RA-induced derivatives in RIPA buffer (10 mM Tris HCL
pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% (v/v) NP40, 0.1%
(w/v) SDS,0.5% (w/v) sodium deoxycholate) and one Complete
mini EDTA-free protease inhibitor cocktail tablets/10 ml RIPA
buffer (Roche Diagnostics Ltd). Protein concentration was de-
termined using the BCATM protein assay kit (Pierce, Rockford,
USA).
Gene Array
Data was normalised using the Lowess curve method, with RA
as the control sample and VPA or LiCl as the treated sample (20%
of the data was used to calculate the Lowess fit at each point).
Probes were filtered by the criteria that in order to pass, the probes
had to possess a Present or Marginal flag in at least 2 out of the 4
samples (4 samples, 2 groups with 2 replicates each). The
remaining probes were used in the statistical filters for the 2
groups VPA and LiCl. A Student T-test applied to the Volcano
plots was used to determine statistically significant differentially
expressed genes from the filtered probes by comparing treatment
with control (2 fold expression cutoff and a p-Value of 0.01).
Realtime PCR
Five genes identified by Microarray analysis were selected for
validation using SYBR green Realtime PCR. Total RNA was
Lithium and VPA in Neural Differentiation
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extracted as above. 1 mg of total RNA was reverse transcribed
using Precision nanoscriptTM reverse transcriptase (Primerdesign,
Southampton UK) and oligo dT primers (PrimerDesign, South-
ampton, UK).
cDNAs were amplified in a standard 40-cycle SYBRH green
real-time PCR reaction using optimised sequence specific pre-
validated primers for Octamer 4 (Pou5F1), metallothionein
(MT1G), mitogen-activated protein kinase 10 (MAPK10/JNK),
NOTCH homologue 1 (NOTCH1) and Nestin (NES). Primers
were supplied by PrimerDesign Ltd (Southampton UK), according
to the manufacturer’s instructions.
GeNorm analysis (PrimerDesign Ltd, Southampton UK) was
carried out to determine a housekeeping gene in which expression
was not affected following treatment of cells. The house keeping
genes Ubiquitin C (UBC), Eukaryotic initiation factor 4A2
(eIF4A2), 18S ribosomal RNA, Glyceraldehyde 3-Phosphate
dehydrogenase (GAPDH), Beta-actin (ACTB), b2 Microglobulin
(B2 M), Uncharacterised protein C14orf133 (VIPAR) and Glu-
cose-6 phosphate dehydrogenase (G6PDH) were tested for stable
expression following treatment of cells. Following analysis
Ubiquitin C (UBC) was selected as a stably expressed gene for
normalisation. The comparative CT method was used to calculate
the relative quantification of gene expression. The following
formula was used to calculate the relative amount of the transcripts
in the chemical treated samples (treat) and the vehicle-treated
samples (control), both of which were normalized to the
endogenous controls. DDCT=DCT (treat) – DCT (control) for
biological RNA samples or DDCT=DCT (HBRR) – DCT
(UHRR) for reference RNA samples. DCT is the difference in
CT between the target gene and endogenous controls by
subtracting the average CT of controls from each replicate. The
fold change for each treated sample (relative to the control sample
(or UHRR) = 2–DDCT. Fold changes in gene expression using the
comparative CT method and statistical analysis were determined
using the freely available Relative Expression Software Tool
(REST 2009, www.qiagen.com).
Gene Ontology (GO) Studies
For pathway analysis of significantly modulated genes (two-
tailed Student’s t-test, p-value ,0.01) MetaCoreTM (GeneGo, San
Diego, USA) software was used. MetaCoreTM is an online software
suite that identifies and visualizes the involvement of differentially
expressed genes in specific cellular pathways, which are sub-
sequently related to the total amount of genes involved in the
particular pathway and in all the available pathways combined
(based upon the relative enrichment of genes and the saturation of
each network with canonical pathways in Metacore GeneGoTM).
Enrichment analysis consists of matching gene IDs of possible
targets for the "common", "similar" and "unique" sets with gene
IDs in functional ontologies in MetaCoreTM. The probability of
a random intersection between a set of IDs the size of target list
with ontology entities is estimated in p-value of hypergeometric
intersection. The ontologies include GeneGo Pathway Maps,
GeneGo Process Networks, GO Processes, GeneGo Diseases (by
Biomarkers). The degree of relevance to different categories for the
uploaded datasets is defined by p-values, so that the lower p-value
gets higher priority.
Hierarchical Cluster Analysis
Unsupervised hierarchical clustering was performed on the
differentially expressed genes common to both VPA and LiCl
treatment using the online expression profiler described by
Kapushesky et al, [16] using the following parameters: Euclidean
distance using average linkage (average distance, UPGMA) and
clustering rows.
Statistical Analysis
Results were expressed as the mean of three samples6 standard
error of the mean (SEM). Comparisons between treatments were
performed using analysis of variance (ANOVA) with the appro-
priate post-test using GraphPad Prism Software. Differences were
considered significant for p values ,0.05.
Results
Microarray Analysis of NT2.D1 Neurosphere Gene
Expression Following Exposure to LiCl and VPA
RNA extracted from the NT2.D1 neurospheres treated with
VPA or LiCl was subjected to microarray analysis using the
Agilent whole genome 44K array. Following normalization the
data was filtered to only include those genes differentially up or
down-regulated by 2 fold or greater (Table S1, Table S2). Among
the numerous genes (164) showing signs of deregulated expression
following treatment with LiCl, 153 were unique (Fig. 1A). In the
LiCl treated neurospheres 73 genes were downregulated and 91
were upregulated (Table S1). In comparison, amongst the
numerous genes (331) showing signs of deregulated expression
following treatment with VPA, 320 were unique (Fig. 1A), of those
114 were down-regulated and 217 genes were up-regulated by
VPA (Table S2). Eleven genes were commonly deregulated by
both VPA and LiCl (Fig. 1A and 1B). These eleven genes were
split into groups by unsupervised hierarchical clustering analysis
(Fig. 1C). Two main groups of up-regulated and down-regulated
genes followed similar patterns in both the LiCl and VPA treated
samples. A third group containing the paxillin (Pxn) encoding gene
demonstrated an upregulation of the paxillin gene (2.70 fold) after
exposure to LiCl with a similar magnitude down-regulation (2.46
fold) after exposure to VPA.
Gene Ontology (GO) Analysis
GO analysis of the LiCl deregulated genes (Table 1) revealed
a significant (p,0.05) overrepresentation of the following GO
process networks; Signal transduction (NOTCH signalling), Cell
cycle (G1-S Interleukin regulation), Cell cycle (G1-S Growth factor
regulation). GO analysis of the VPA deregulated genes (Table 2)
revealed a significant (p,0.05) overrepresentation of the following
GO process networks; Cell adhesion (Cell junctions), Cell adhesion
(Amyloid proteins), Development (Blood vessel morphogenesis),
Development (Regulation of epithelial-to-mesenchymal transition),
Proliferation (Negative regulation of cell proliferation), Cytoskel-
eton (Intermediate filaments) and Development (Neurogenesis:Sy-
naptogenesis).
Validation of Microarray Results Using Real-Time PCR
To assess the validity of altered expression of genes identified by
Agilent’s Whole human 44K genome microarray analysis, we
selected five genes for subsequent analysis by SYBR Green Real
time PCR. Four genes that were changed in both gene sets upon
analysis of the array data were included in addition to the gene
Pou5F1, which was included to corroborate changes seen in the
array data and the upregulation of expression of the protein
product of this gene (Oct4) when analysed by flow cytometry.
Genes included: Pou5F1, MT1G, MAPK10, NOTCH1 and NES.
Genes expected to be upregulated by VPA and LiCl were
significantly (p,0.05) induced (Table 3). Similarly, the genes
expected to be downregulated by VPA and LiCl were significantly
(p,0.05) decreased with the exception of NOTCH (p.0.05)
Lithium and VPA in Neural Differentiation
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(Table 3). Whilst a reduction in NOTCH1 expression was not
found to be significant by Real Time PCR a reduction in
expression was observed which was in agreement with the array
data.
Figure 1. Venn diagram summarising the number of significantly differentially expressed genes unique and common to VPA+RA
and LiCl+RA treatment (A). Tabulated fold change and p-value data (B) and unsupervised hierarchical cluster analysis (C) for the eleven genes
found to be significantly up-regulated (red) or down-regulated (blue) in response to both to VPA and LiCl treatment.
doi:10.1371/journal.pone.0058822.g001
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Proliferation of Cells Following Exposure to LiCl and VPA
Our previous data [7] did not demonstrate a significant increase
in cell number using Cell Titre Blue following treatment of cells
with LiCl at day 14 and only a modest ,30% decrease in cell
viability following treatment with VPA. However direct cell
counting using a haemocytometer (Fig. 2) of dissociated neuro-
spheres showed a significant increase (p,0.01) in the number of
cells derived from neurospheres treated with 1 mM LiCl to
140.6613.3% of RA treated control. In addition, there was
a significant (p,0.001) decrease in the number of cells following
treatment with VPA to 2062.9% of the RA treated control. This
data was also verified using flow cytometry (data not shown).
Regarding the differences identified between direct cell counting
and indirect measures such as cell viability used previously, we
would now question the validity of using Cell Titre blue as
a measure of cell number in 3D culture. To further validate the
results of direct cell counting we also measured total protein and
demonstrated almost identical results as that seen by direct cell
counting (data not shown). This data would correlate with the
changes in neurosphere size (increase with LiCl and a decrease
with VPA) that were observed following exposure to toxins in both
this and our previous study [7]. Whilst an increase in the number
of cells could be correlated with just an increase in size, it is also
possible that an increase in the number of neurospheres could also
be responsible for the differences observed. As there is a wide
distribution in the size and number of neurospheres, a measure of
total cell numbers was found to be the most accurate method to
determine cell proliferation.
Cell Cycle Analysis of Cells Exposed to LiCl and VPA
Cell cycle analysis of cells exposed to LiCl using propidium
iodide staining showed no significant changes compared to the
control (Fig. 3). Conversely, cells treated with VPA showed
a significant decrease (p,0.05) in the number of cells at the G2/M
phase of the cell cycle.
Flow Cytometry Analysis of Cells Treated with LiCl and
VPA
Flow cytometry analysis of cells was used to determine the
proportions of cells expressing stem cell associated markers (Oct4,
SSEA4), a neuronal marker (NFM) and an astrocytic marker
(GFAP) in both undifferentiated NT2.D1 cell, as well as RA and
RA+toxicant treated neurospheres (Fig. 4). Undifferentiated
NT2.D1 cells contain 70.764.9% and SSEA4, 97.360.7% Oct4
positive cells with no staining for GFAP or NFM. Differentiation
with RA induces a significant reduction (p,0.001) in the levels of
these pluripotentcy associated markers and an increase in the
levels of cells expressing GFAP and NFM. Treatment with LiCl
demonstrated no significant change in the proportions of cells
expressing any of the markers tested from the RA treated control,
Table 1. Functional annotational clustering of genes enriched in NT2.D1 neurospheres following treatment with LiCl.
GO process network Genes included in GO term p value
Signal transduction_NOTCH signaling CD44, DIP-1, ErbB3, JNK, Notch, p63, TGF-beta receptor type II 1.5E–4
Cell cycle_G1-S Interleukin regulation Cyclin A, JNK, p14ARF, p15, p16INK4, STAT6 1.8E–4
Cell cycle_G1-S Growth factor regulation Cyclin A, G-Protein alpha(i) family, JNK, p14ARF, P15, p16INK4, TGF-beta
receptor type II
6.6E–4
MetacoreTM (GeneGo) was used for this analysis using genes that were statistically significant p,0.05. Pathways with a p-value ,0.05 were considered significantly
modulated.
doi:10.1371/journal.pone.0058822.t001
Table 2. Functional annotational clustering of genes enriched in NT2.D1 neurospheres following treatment with VPA.
GO process network Genes included in GO term p value
Cell adhesion_Cell junctions Actin, Claudin-11, Claudin-7, desmoplakin, E-cadherin, EPB-41, keratin-18, keratin-8, Paxillin,
PKC, Plakophilin-3, ZO-3
1.3E–05
Cell adhesion_Amyloid proteins WNT, NOTCH, APLP2, G-alpha(q)specific frizzled GPCR, PKC, E-Cadherin, cortactin,
X11-like, Actin
1.8E–05





Notch, G-alpha(q)specific frizzled GPCR, Actin, Desmoplakin, E-cadherin, GSC, Keratin 18,
keratin 8, MAP2K7, MMP-9, Nestin, Notch1, SHP-2, WNT
5.1E–05
Proliferation_Negative regulation of cell
proliferation
BINPL, Calgizzarin, FRK, Galpha(i)-specific peptide GPCR, IBP, MAD3, MAD4, Pitx2, SHP-1,
SSTR2, VHL
2.0E–04
Cytoskeleton_Intermediate filaments Actin, desmoplakin, keratin 18, keratin 8, kinesis light chain, nestin 2.0E–3
Development_Neurogenesis:Synaptogenesis Actin, Atrophin 1, Chapsyn-110, Cortactin, G-alpha(q)specific frizzled GPCR, N-type Ca(II)
channel alpha1B, neuroligin, synaptotagmin, VAMP8, WNT, X11-like
2.0E–3
Cell adhesion_Cadherins Actin, Cortactin, E-Cadherin, G-alpha(q)specific frizzled GPCR, k-cadherin, PKC, plakophilin,
SHP-1, SHP-2, SWAP-70, WNT
2.0E–3
Development_Neurogenesis in general FZD-5, G-alpha(q)specific frizzled GPCR, GFRalpha2, Nestin, Notch, PBX1, WNT 3.5E–3
MetacoreTM (GeneGo) was used for this analysis using genes that were statistically significant p,0.05. Pathways with a p-value ,0.05 were considered significantly
modulated.
doi:10.1371/journal.pone.0058822.t002
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despite a significant increase in the number of cells. In contrast,
treatment with VPA resulted in a significant increase (p,0.001) in
all of the markers tested compared to the RA treated control.
Discussion
Well-characterized risks are associated with administration of
VPA and LiCl during pregnancy. The rate for major congenital
malformations for foetuses exposed to VPA is documented as
approximately 6%–20% [17]. Whilst LiCl has been shown to
disrupt development in diverse organisms, LiCl-related birth
defects are rare in humans, but However, foetal exposure to LiCl
in the first trimester may be associated with a small increased risk
of Ebstein’s anomaly [18]. Whilst LiCl has no reported de-
velopmental neurobehavioural effects, VPA-exposed children are
three times more likely to require special education than controls
[17].
In this preliminary study, the regulation of gene expression
following chronic treatment with VPA and LiCl was explored in
a neurosphere-based model of neurogenesis [7]. Phenotypic
parameters including cell population changes, and cell cycle
progression were also studied.
Cross-talk between cell signalling pathways is essential for
measured and appropriate responses to stimuli and stress. This,
therefore, requires the coordinated regulation of the expression of
genes encoding integrated pathway components. Gene expression
profiling therefore has the potential to reveal the molecular
pathways that mediate the adverse responses to a toxicant. The
initial output of toxicogenomics consists of a list of genes whose
expression is altered upon toxicant exposure. In order to interpret
this data in a biological context, bioinformatic methods such as
GO mapping and pathway analysis can be used to complement
gene expression profiling data [19].
In this study, gene expression analysis revealed only 11 common
genes are shared by both LiCl and VPA. GO enrichment revealed
that these shared genes are highly enriched in Wnt signalling
through b-Catenin. This is perhaps unsurprising as VPA and LiCl
inhibit the activity of glycogen synthase kinase 3 b (GSK3b). LiCl
has been shown to be a direct, reversible inhibitor of GSK-3b with
an IC50 value of ,2 mM [20], as it acts through competitive
inhibition of Mg2+. LiCl administered to mice has been shown to
indirectly cause an increase in the phosphorylation of Ser9 of
GSK-3b in vivo. As with LiCl, VPA has also been reported to
inhibit GSK-3b enzymatic activity and induce GSK-3bSer9
phosphorylation [21]. However, the finding that .90% of the
genes altered by VPA and LiCl are unique would suggest that
these two compounds exert their developmental actions by
alternate mechanisms as evidenced by the overt phenotypic
differences observed.
GO analysis using MetaCoreTM (GeneGo) was used to identify
enriched biological processes within differentially expressed genes.
Biological processes such as signal transduction and cell cycle
regulation were highlighted as the most significant GO categories
following treatment with lithium. We also showed an increase in
cell number following treatment with LiCl compared to the RA
control. GO process network analysis of the LiCl treated cells also
highlighted genes involved in cell cycle G1-S regulation which
were affected by LiCl treatment. The increase in cell number
associated with LiCl treatment would suggest cell cycle changes.
However, whilst an increase in cell number was observed in this
study, there were no significant changes in the cell cycle profile at
14 days differentiation. All cell treatments demonstrated a G0/G1
block which is one of the major effects of RA on multiple cell types
[22] including EC cells [23] and appears to dominate the cell-cycle
Table 3. Validation of microarray data using Real Time PCR.
VPA Lithium
Gene N-Fold SEM (6) p Value N-Fold SEM (6) p Value
POU5F1 10.85 2.06 ,0.05 1.81 0.13 ,0.05
MT1G 15.30 3.58 ,0.05 1.56 0.03 ,0.05
MAPK10 23.23 0.02 ,0.05 21.23 0.08 ,0.05
NOTCH1 22.20 0.04 .0.05 21.70 0.03 .0.05
NES 24.48 0.01 ,0.05 1.04 0.14 ,0.05
Data is expressed as fold expression changes of Pou5F1, MT1G, MAPK10,
NOTCH1 and NES. Results are shown as fold change 6S.E.M (n = 3). Genes with
a p-value ,0.05 were considered significantly modulated.
doi:10.1371/journal.pone.0058822.t003
Figure 2. Total number of cells from dissociated neurospheres
following treatment with VPA+RA and LiCl+RA as a percentage
of the RA treated control. Cell populations of dissociated neuro-
spheres post treatment with VPA (0.5 mM) and LiCl (1.0 mM). Results
are shown as 6 S.E.M (n = 3). p,0.05(*), p,0.01(**), p,0.001(***). p
values were calculated by One-way ANOVA and corrected for multiple
comparisons by Dunnets’s post-test in comparison to the RA only
control.
doi:10.1371/journal.pone.0058822.g002
Figure 3. Cell cycle analysis of RA, LiCl+RA and VPA+RA treated
cells. Cell populations of dissociated neurospheres in each cell cycle
phase post treatment with VPA (0.5 mM) and LiCl (1.0 mM) and total
cell number as a percentage of control cells post lithium and VPA
treatment results are shown as 6 S.E.M (n = 3). p,0.05(*), p,0.01(**),
p,0.001(***). p values were calculated by One-way ANOVA and
corrected for multiple comparisons by Bonferroni’s multiple comparison
post-test in comparison to the RA only control.
doi:10.1371/journal.pone.0058822.g003
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profile at day 14 of differentiation regardless of treatment. Future
experiments will aim to determine the effects of LiCl on early cell
cycle changes.
VPA exposure during the first trimester of pregnancy increases
the risk for spina bifida aperta, a result of the failure of the posterior
neural tube closure [24]. Several intracellular pathways, including
the Ras-ERK pathway [25], have been shown to be affected by
VPA, however, its major targets in the cells were found to be
histone deacetylases (HDACs) [26,27] and GSK3b [28]. The
mechanism of teratogenicity is clearly distinct from that of the
antiepileptic activity because VPA derivatives exist which are
preferentially either teratogenic, such as S-4-yn-VPA, or antiep-
ileptic, such as Valpromide (VPD). This is consistent with the
proposition that disruption of proper embryonic development by
VPA, but not the antiepileptic activity, is due to HDAC inhibition
[29].
Treatment of neurospheres with VPA led to derangement of
significantly more genes than LiCl. In addition, more overt
phenotypic changes were also associated with this toxin in terms of
cell number, protein expression and cell cycle stage. GO analysis
was able to identify enriched biological processes within differen-
tially expressed genes. Processes which are crucial during de-
velopment such as cell adhesion, proliferation, cytoskeleton and
development were highlighted as the most significant GO-
categories.
In this study VPA treatment resulted in a significant decrease in
cell number. VPA has been previously reported to regulate the
differentiation and proliferation of neural progenitor and neuro-
blastoma cells [25,30,31]. It has been suggested that these effects
are mediated by the ERK-p21CIP/WAF1 pathway [25].
Cell adhesion, cell polarity and cytoskeletal organisation play
a fundamental role in driving morphogenesis in gastrulation and
are essential in establishing the architecture of vertebrate embryos
[32]. VPA has previously been shown to disrupt cell morphology
and motility through interference with dynamics of the actin
cytoskeleton [33]. Indeed, it has been shown that aberrations in
these processes can result in neural tube defects [34]. The
dynamics of adherens junctions and focal adhesions are controlled
by the assembly and disassembly of adhesion components coupled
with cytoskeletal remodelling actin organisation [35,36]. In
support of these findings, we observed changes in numerous genes
associated with cell adhesion and the cytoskeleton in cells treated
with VPA (Table 2). Previous studies using this system [7]
identified significant changes in size and morphology of neuro-
spheres which may have been linked with changes in cell adhesion
and cytoskeletal organisation.
In accordance with the array data, flow cytometry indicated
significant increases in the stem cell markers Oct4 and SSEA4 in
the VPA treated neurospheres. Interestingly flow cytometric
analysis revealed that the increase in the expression of the Pou5F1
Figure 4. Proportion of cells expressing SSEA4, Oct4, GFAP and NFM following treatment with VPA+RA and LiCl+RA measured
using flow cytometry. Number of cells expressed as a percentage of total number of cells A) Undifferentiated NT2.D1 cells, B) RA, C) LiCl (1 mM)
and D) VPA (0.5 mM). Results are shown as 6S.E.M (n = 3). p,0.05(*), p,0.01(**), p,0.001(***). p values were calculated by One-way ANOVA and
corrected for multiple comparisons by Bonferroni’s multiple comparison post-test in comparison to the RA only control.
doi:10.1371/journal.pone.0058822.g004
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gene seen in the array (13 fold) and PCR was correlated with an
increase in the population of Oct4 expressing cells with a 5 fold
increase in the number of cells positive for Oct4. It is has been
shown previously that VPA specifically targets the proximal
promoter region of Oct4 to activate its expression [37]. Indeed,
VPA has been shown to improve reprogramming efficiency of
induced pluripotent stem cells more than 100 fold using Oct4-GFP
as a reporter [38]. The paradoxical expression of stem cell markers
as well as differentiation markers such as GFAP and NFM could
be explained by the nature of VPA in that it can directly drive the
expression of Oct4 whilst concomitantly driving cell cycle exit and
neural differentiation.
In summary, the gene changes highlighted in this study in
combination with measurable phenotypic changes demonstrates
the potential of combining expression profiling, GO analysis and
phenotypic anchoring. We demonstrate that this approach may
serve to enhance identification of biomarkers/pathways associated
with the pharmacology and DNT of LiCL and VPA. Future
studies will identify the temporal nature of these changes in order
to fully understand the mechanism of action of these compounds.
In addition, we will also determine the functional effects of these
compounds on neurons and astrocytes derived from these cultures
[39]. Following further validation with a larger range of toxins this
approach may prove useful for identifying potential developmental
neurotoxins as part of a battery of tests for regulatory screening
processes.
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